Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602025139> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2602025139 abstract "e16110 Background: Sunitinib, an inhibitor of multiple tyrosine kinases, is FDA approved for metastatic renal cell cancer (mRCC). Though better tolerated than historical therapies, sunitinib is associated with adverse events (AEs) that may require dose modifications (DM). We sought to identify 1) baseline patient (pt) characteristics that predispose for DM, 2) the most common AEs requiring DM in a non-protocol setting, and 3) the impact of dose limiting AEs on treatment continuation. Methods: Single-center, retrospective chart review. Pts ≥ 18 years of age with mRCC of clear-cell histology on sunitinib therapy with active follow-up at MDACC were eligible. Univariate and multivariate logistic regression analysis of 66 pt variables (demographics, laboratory analysis, past medical and treatment history, etc) and dose-limiting AEs was completed, with a 6 month endpoint of sunitinib continuation, alternative therapy, or death. Results: From January 1, 2006 through September 30, 2007, 146 pts were identified meeting eligibility criteria. By univariate analysis, increased age (p=0.04; OR 1.04, 1.002–1.081 CI) and elevated BUN (p=0.03; OR 1.06, 1.006 –1.108 CI) were directly associated with increased incidence of dose-limiting AEs. ECOG PS of 2 (p=0.04; OR 0.3, 0.114–0.951 CI) was associated with a decreased incidence of dose limiting AEs. In a multivariate analysis, only BUN remained significant. 57% of patients (n= 83) had dose-limiting AEs. DM were often attributed to multiple AEs (55%), with fatigue, mucositis, hand-foot syndrome and nausea being the most common. At 6 months follow-up, 63% of pts with dose-limiting AEs remained on sunitinib vs. 37% (p=0.18). There was no difference in death rate at 6 months between the two groups. Conclusions: Elevated baseline BUN is associated with an increased rate of DM in patients with RCC receiving sunitinib. Despite the high-incidence of AEs, pts can be maintained on sunitinib with DM and without an adverse impact on outcome. Whether specific AEs are biologic indicators of activity should be evaluated in a larger clinical trial. [Table: see text]" @default.
- W2602025139 created "2017-04-07" @default.
- W2602025139 creator A5003828930 @default.
- W2602025139 creator A5007689146 @default.
- W2602025139 creator A5009021249 @default.
- W2602025139 creator A5012372745 @default.
- W2602025139 creator A5058115259 @default.
- W2602025139 date "2009-05-20" @default.
- W2602025139 modified "2023-09-25" @default.
- W2602025139 title "Patient characteristics associated with dose-limiting sunitinib adverse events" @default.
- W2602025139 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e16110" @default.
- W2602025139 hasPublicationYear "2009" @default.
- W2602025139 type Work @default.
- W2602025139 sameAs 2602025139 @default.
- W2602025139 citedByCount "0" @default.
- W2602025139 crossrefType "journal-article" @default.
- W2602025139 hasAuthorship W2602025139A5003828930 @default.
- W2602025139 hasAuthorship W2602025139A5007689146 @default.
- W2602025139 hasAuthorship W2602025139A5009021249 @default.
- W2602025139 hasAuthorship W2602025139A5012372745 @default.
- W2602025139 hasAuthorship W2602025139A5058115259 @default.
- W2602025139 hasConcept C121608353 @default.
- W2602025139 hasConcept C126322002 @default.
- W2602025139 hasConcept C143998085 @default.
- W2602025139 hasConcept C151956035 @default.
- W2602025139 hasConcept C167135981 @default.
- W2602025139 hasConcept C197934379 @default.
- W2602025139 hasConcept C203092338 @default.
- W2602025139 hasConcept C2778820342 @default.
- W2602025139 hasConcept C2779490328 @default.
- W2602025139 hasConcept C535046627 @default.
- W2602025139 hasConcept C71924100 @default.
- W2602025139 hasConceptScore W2602025139C121608353 @default.
- W2602025139 hasConceptScore W2602025139C126322002 @default.
- W2602025139 hasConceptScore W2602025139C143998085 @default.
- W2602025139 hasConceptScore W2602025139C151956035 @default.
- W2602025139 hasConceptScore W2602025139C167135981 @default.
- W2602025139 hasConceptScore W2602025139C197934379 @default.
- W2602025139 hasConceptScore W2602025139C203092338 @default.
- W2602025139 hasConceptScore W2602025139C2778820342 @default.
- W2602025139 hasConceptScore W2602025139C2779490328 @default.
- W2602025139 hasConceptScore W2602025139C535046627 @default.
- W2602025139 hasConceptScore W2602025139C71924100 @default.
- W2602025139 hasLocation W26020251391 @default.
- W2602025139 hasOpenAccess W2602025139 @default.
- W2602025139 hasPrimaryLocation W26020251391 @default.
- W2602025139 hasRelatedWork W1985943243 @default.
- W2602025139 hasRelatedWork W2130532651 @default.
- W2602025139 hasRelatedWork W2150963444 @default.
- W2602025139 hasRelatedWork W2170339563 @default.
- W2602025139 hasRelatedWork W2480362970 @default.
- W2602025139 hasRelatedWork W2528407746 @default.
- W2602025139 hasRelatedWork W2570719551 @default.
- W2602025139 hasRelatedWork W2589164886 @default.
- W2602025139 hasRelatedWork W2590044683 @default.
- W2602025139 hasRelatedWork W2590340566 @default.
- W2602025139 hasRelatedWork W2590523888 @default.
- W2602025139 hasRelatedWork W2747947255 @default.
- W2602025139 hasRelatedWork W2900441895 @default.
- W2602025139 hasRelatedWork W2905004070 @default.
- W2602025139 hasRelatedWork W2923738693 @default.
- W2602025139 hasRelatedWork W2949144648 @default.
- W2602025139 hasRelatedWork W2991779408 @default.
- W2602025139 hasRelatedWork W2996164021 @default.
- W2602025139 hasRelatedWork W3030472743 @default.
- W2602025139 hasRelatedWork W2181537583 @default.
- W2602025139 isParatext "false" @default.
- W2602025139 isRetracted "false" @default.
- W2602025139 magId "2602025139" @default.
- W2602025139 workType "article" @default.